Overall, immunotherapy is a strategy that is currently promising for HNSCC patients and based on recent clinical data with T-cell checkpoint inhibitors (anti-PD1) [66, 67], it is clear that promoting an active anti-tumor immune response can be highly therapeutic. Here, PDCD1 is linked to head and neck squamous cell carcinoma.